The Burrill Report
The Burrill Report (April 22, 2013): Back to that Same Old Place (.MP3,17.02 Mb)
As the BIO International Convention gets underway in Chicago April 22, the industry’s biggest companies are trading at record highs, the U.S. Food and Drug Administration has picked up the pace of new drug approvals, and potential new products in development offer reasons for enthusiasm. But financing remains challenging, global intellectual property and regulatory issues are growing, and the challenge of securing rewards for innovation remains a concern. We spoke to Jim Greenwood, president and CEO of the Biotechnology Industry Organization, about the state of the industry on the eve of the convention, the policy matters before it, and what’s ahead in the coming year.
April 18, 2013